Finally, in a meta-analysis of randomized controlled trials, SGLT-2 decreased albuminuria, slowing the progression of microalbuminuria to macroalbuminuria and reducing the risk of end-stage renal disease [41]. Here, SLC5A2 is linked to chronic kidney disease.